Each vial contains 0.1 mg IgE in 0.1 ml (1 mg/ml) of PBS pH7.4, 0.1% BSA with 0.09% sodium azide. Antibody was purified by Protein-L affinity chromatography. 1 mg Human IgE corresponds to 380,000 ± 50,000 IU/ml. Biotinylation ratio: 2-4 biotin/IgE.
保存条件:
Store at -20°C. The material must be handled as potentially infectious as all human material.
This product is purified human IgE with kappa light chains produced in vitro from a hybridoma. Plasma IgE concentrations are low in normal patients. Elevated IgE levels are found in patients presenting severe allergic reactions and parasite infections. Original material was obtained from a healthy donor tested negative for HIV, HCV and hepatitis B by using US FDA-approved tests. Purity of human IgE is > 98% by SDS-PAGE analysis. There is no contamination by antibodies of other isotypes because of the cell line origin. Contaminants from foetal bovine serum were removed by Protein-L affinity chromatography. The material must be handled as potentially infectious as all human material. The product can be used as an IgE control in quantitative assays and for cell sensitization assays.
克隆类型:
Human Ig, Biotin-conjugated Antibody, Control Antibody
亚型:
Human IgE
免疫原:
This is a non-immune hybridoma.
适用物种:
H
应用范围:
E
应用说明:
Purified human IgE with kappa light chain is produced in vitro from a monoclonal hybridoma. Original material was obtained from a healthy donor tested negative for HIV, HCV and hepatitis B by using US FDA-approved tests. Purity of human IgE is >98% by SDS-PAGE analysis. Endotoxin level < 25 EU/mg.
别名:
Immunoglobulin E; IgE
形态:
Each vial contains 0.1 mg IgE in 0.1 ml (1 mg/ml) of PBS pH7.4, 0.1% BSA with 0.09% sodium azide. Antibody was purified by Protein-L affinity chromatography. 1 mg Human IgE corresponds to 380,000 ± 50,000 IU/ml. Biotinylation ratio: 2-4 biotin/IgE.
保存条件:
Store at -20°C. Minimize freeze-thaw cycles. The material must be handled as potentially infectious as all human material. Product is guaranteed one year from the date of shipment.
参考文献:
[1] Janson C et al. 2012. PLoS ONE. 7(11):e49615. PMID# 23185384. [2] Ainsua-enrich e et al. 2012. Journal of Immunology. 189(6):2727-2734. PMID# 22896635. [3] Serra-Pages M et al. 2012 Journal of Leukocyte Biology. 92(6):1155-1165. PMID# 2285983. [4] Alvarez-Errico D et al. 2011. The Journal of Immunology. 187(11):5577-5586. PMID# 22068234. [5] Charles N et al. 2010. Nature Medicine. 16(701-707.PMID# 20512127.